-
Biotech Investors Shouldn't Fear Legislation, Even If Hillary Is President And Dems Win Senate Majority
Wednesday, February 24, 2016 - 12:00pm | 382Read More...In a new report, Evercore ISI analyst Terry Haines discussed the potential for some form of drug pricing legislation in the U.S. within the next two years. The SPDR S&P Biotech (ETF) (NYSE: XBI) is down 35.3 percent in the past six months since Democratic presidential front-runner Hillary...
-
Valeant Trends Down Following Oversight Committee Release Of Docs
Tuesday, February 2, 2016 - 1:51pm | 209Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were trading lower by more than 3 percent early Tuesday afternoon following the release of a memorandum from the U.S. Committee on Oversight and Government Reform. The memorandum, titled "Documents Obtained by Committee from Valeant...
-
Express Scripts Calls Out Valeant, Says It's 'Holding Pharmaceutical Manufacturers Accountable For Excessive Price Hikes'
Friday, January 29, 2016 - 2:03pm | 363Read More...Express Scripts Holding Company (NASDAQ: ESRX), the largest pharmacy benefit management organization in the U.S., announced on Friday it has decided to exclude Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s Glumetza from its formulary. Express Scripts noted that throughout Valeant...
-
Massachusetts Attorney General To Gilead Sciences: Cost Of Harvoni & Sovaldi Drugs 'May Constitute An Unfair Trade Practice In Violation Of Massachusetts Law'
Wednesday, January 27, 2016 - 3:16pm | 259Read More...According to The Boston Globe, Massachusetts Attorney General Maura Healey wrote a letter to Gilead Sciences, Inc. (NASDAQ: GILD) which suggested her office could initiate legal action. The Boston Globe noted that Healey's letter was dated January 22 and delivered to Gilead's CEO John...
-
Bill Ackman: Valeant Is 'Enormously' Undervalued
Wednesday, December 16, 2015 - 10:31am | 484Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) have gained more than 45 percent over the past month, but are still lower by around 24 percent since the start of 2015. Valeant's stock crashed to a multi-year low of $69.33 following scathing allegations from Citron Research, statements from...
-
Express Scripts Prefers This $1 Alternative To Daraprim
Tuesday, December 1, 2015 - 11:28am | 478Read More...Martin Shkreli, CEO of Turing Pharmaceuticals, controversially raised the price of a potentially life-saving drug called Daraprim to $750 a pill from $13.50. Express Scripts Holding Company (NASDAQ: ESRX), the largest manager of prescription drug benefits, said on it will now cover a $1 a...
-
Valeant Could See Volatile Trading, But BofA Is Still Bullish
Thursday, October 15, 2015 - 12:40pm | 410Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were lower by more than 6 percent Thursday and now down nearly 30 percent over the past three months. Valeant announced on Wednesday it has responded to government inquiries into its drug pricing practices. Sumant Kulkami of Bank of...
-
How To Invest During Biotech's Latest Crisis
Friday, October 9, 2015 - 11:25am | 554Read More...Shares of the biotechnology ETF, iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB), have lost more than 15 percent over the past three months. The sector has been hard hit following a "drug pricing crisis," according to Irina Koffler of Mizuho Securities who initiated coverage...
-
Citron Research: Don't Bother Senator Sanders, Here's What A Subpoena On Valeant Would Expose
Friday, October 2, 2015 - 1:19pm | 528Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were trading lower by more than 3 percent Friday morning. Shares of Valeant have come under pressure over concerns of price gouging and a plea for a subpoena by Bernie Sanders to see all communication regarding price hikes. Citron Research...
-
2 Pharma Stocks To Hide In While Drug Pricing Fears Play Out
Tuesday, September 29, 2015 - 1:37pm | 387Read More...Drug pricing remains a concern within the pharmaceutical sector. Liav Abraham of Citi commented in a note on Monday that recent negative headlines are "unhelpful" to investor sentiment. Abraham suggested investors can "hide" in Allergan PLC (NYSE: AGN) and Teva Pharmaceutical Industries Ltd (ADR...
-
Stifel Reiterates Horizon Pharma As 'Select List' Pick, Sees 'Buying Opportunity In Multiple Misguided Reactions'
Wednesday, September 23, 2015 - 8:50am | 449Read More...Shares of Horizon Pharma PLC (NASDAQ: HZNP) have come under "inordinate pressure" in the last few days, according to Annabel Samimy of Stifel. Samimy maintained a Buy rating and $45 price target on the stock. According to Samimy, Horizon is "one of the stronger diversified...
-
Don't Worry Investors, Hillary Can't Change Drug Pricing As President
Monday, September 21, 2015 - 3:59pm | 506Read More...Hillary Clinton tweeted that "price gouging" in the specialty drug market is "outrageous." Terry Haines of Evercore ISI commented in a note that there is "almost no chance" of a president legislating drug pricing regulation. An appeal by Democratic candidate to "control" or "gauge" drug pricing...
